PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta s Scientific Advisory Board
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative . Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology,.
Whole Foods Market, Inc. (NASDAQ: WFM) s changes to its executive team and 2020 guidance is receiving a mixed reaction from Wall Street.
Analysts at Credit Suisse argued that Whole Foods new changes aren t perfect but good enough to help the stock. Analysts at Deutsche Bank are taking. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
Crypto News Recap: Bitcoin Loses Steam as Price Corrects to $32,979 in a Brutal Volatile Swing! albawaba.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albawaba.com Daily Mail and Mail on Sunday newspapers.